A61K39/105

Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production

Provided are methods for rapidly inactivating a pathogen, or for producing a vaccine composition containing an inactivated noninfectious pathogen having retained antigenicity and/or immunogenicity, comprising exposing the pathogen to a chemical inactivating agent (e.g., one or more chemical oxidizing, alkylating or crosslinking agents) in the presence of inorganic polyatomic oxyanions in an amount and for a time sufficient to render the pathogen noninfectious while enhancing retention of pathogen antigenicity and/or immunogenicity relative to that retained by contacting the pathogen with the chemical inactivating agent alone. The methods are broadly applicable to pathogens having RNA or DNA genomes (e.g., including viruses, bacteria, fungi, and parasites). Also provided are vaccine compositions (medicaments) containing a pathogen inactivated by exposure to an inactivating agent in the presence of elevated concentrations of inorganic polyatomic oxyanions, and methods for eliciting an immune response in a subject by administering the vaccine compositions.

Bioconjugates Made From Recombinant N-Glycosylated Proteins From Procaryotic Cells

The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.

IMMUNOGENIC COMPOSITIONS COMPRISING LAWSONIA INTRACELLULARIS
20210030863 · 2021-02-04 ·

The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.

Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells

The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.

<i>Helicobacter pylori </i>vaccines

The present invention relates to immunogenic compositions and their use in the prevention or treatment of diseases or disorders caused by or associated with Helicobacter pylori, in particular H. pylori infection and gastroduodenal disorders caused by H. pylori. The present invention further relates to methods of detecting H. pylori infection in a subject.

Preparation of live vaccines

Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method.

PCV/MYCOPLASMA HYOPNEUMONIAE VACCINE

This invention provides a combination vaccine which includes a porcine circovirus type 2 (PCV2) antigen and a cell free Mycoplasma hyopneumoniae (M.hyo) culture supernatant for protecting a pig against PCV2 and M.hyo infections, wherein the M.hyo culture supernatant is substantially free of PCV2 antibodies.

Campylobacter Immunogenic Compositions and Uses Thereof
20200317737 · 2020-10-08 ·

The present disclosure provides immunogenic compositions against Campylobacter and methods for using the immunogenic composition to generate an immune response against Campylobacter and/or reduce intestinal colonization by Campylobacter.

Method for reducing skatole and/or indole in animals
10792352 · 2020-10-06 ·

The present invention relates i.a. to a method for reducing the concentration of skatole and/or indole in an animal comprising administering to said animal an effective amount of an immunogenic composition comprising Lawsonia intracellularis antigen. Therefore, the present invention also relates to methods for reducing pork odor or boar taint.

COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO ENTERIC PATHOGENS

Vaccine vectors capable of eliciting an immune response to enteric bacteria and methods of using the same are provided. The vaccine vectors include a polynucleotide encoding a PAL polypeptide. The PAL polypeptide may be expressed on the surface of the vaccine vector. The vaccine vector may also include a second polypeptide encoding an immunostimulatory polypeptide such as a CD154 polypeptide or an HMGB1 polypeptide.